SCHEMBL9900539

SCHEMBL9900539

CSc1nc(Cl)cc(N2CCC(NC(=O)O)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
LMNA P02545 1/20 0.48
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
SMO Q99835 4/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31451895 0.90 KMT2A (0.55) KMT2ALMNAMAPTKDM4ERXFP1
SCHEMBL3281559 0.85 HRH4 (0.44) LMNAMAPTKDM4ERXFP1SMN1; SMN2
SCHEMBL9942509 0.85 CKS1B (0.52) KMT2ALMNACKS1BSKP1SKP2
SCHEMBL3281578 0.82 ADORA2A (0.44) KMT2AMAPTKDM4ERXFP1SMN1; SMN2
SCHEMBL5153329 0.81 LMNA (0.67) KMT2ALMNAMAPTSMN1; SMN2HTT
SCHEMBL9900428 0.80 LMNA (0.47) LMNASMN1; SMN2USP2HPGDALDH1A1
SCHEMBL5220298 0.79 LMNA (0.46) KMT2ALMNASMN1; SMN2USP2HPGD
SCHEMBL31451916 0.79 KMT2A (0.71) KMT2ALMNAMAPTKDM4ERXFP1
SCHEMBL27908906 0.78 KMT2A (0.62) KMT2ALMNAMAPTKDM4ERXFP1
SCHEMBL29998765 0.78 LMNA (0.51) KMT2ALMNAMAPTSMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 KMT2A 663/4885LMNA 2103/4885MAPT 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.